SCHEMBL3586576

SCHEMBL3586576

C[Si](C)(C)C(C(N)=O)[Si](C)(C)C.[LiH]

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222605 0.97 LMNA (0.35) LMNAALOX15BLMPMP22
SCHEMBL11142184 0.80
SCHEMBL3645450 0.71 LMNA (0.35) LMNAALOX15BLMPMP22
SCHEMBL8312889 0.71 LMNA (0.30) LMNAALOX15BLMPMP22
SCHEMBL5435336 0.71 CA1 (0.34) LMNAALOX15BLMPMP22
SCHEMBL5477218 0.69
SCHEMBL4746690 0.69 TDP1 (0.41)
SCHEMBL10583658 0.69
SCHEMBL7098668 0.69
SCHEMBL5050650 0.67 TP53 (0.39) LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668155-B1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2668155-A2 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 EP disclosed
US-8592426-B2 Aryl-benzocycloalkyl amide derivatives Hoffmann—La Roche Inc. (US) 2013-11-26 US disclosed
US-20130018055-A1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-01-17 US disclosed
WO-2012101011-A2 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 WO disclosed
US-7759372-B2 Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2010-07-20 US disclosed
EP-2033952-A1 Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity Shionogi&Co., Ltd. (JP) 2009-03-11 EP disclosed
EP-1375486-B1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-20060293334-A1 Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase FUJI MASAHIRO 2006-12-28 US disclosed
US-7148237-B2 Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2006-12-12 US disclosed
EP-1375486-A1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2004-01-02 EP disclosed
EP-0759437-B1 PROCESSES FOR THE PRODUCTION OF 2-ISOCEPHEM DERIVATIVES OTSUKA KAGAKU KK (JP) 2003-06-04 EP disclosed
US-20020115669-A1 Oxazolidinone chemotherapeutic agents ABBOTT LABORATORIES 2002-08-22 US disclosed
EP-1201670-A2 Process for preparing 2-oxaisocephem derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2002-05-02 EP disclosed
WO-2002018354-A1 OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS ABBOTT LABORATORIES (US) 2002-03-07 WO disclosed
US-6063918-A Process for preparing 2-isocephem derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2000-05-16 US disclosed
US-5688942-A Process for preparing 2-isocephem derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1997-11-18 US disclosed
EP-0759437-A1 PROCESSES FOR THE PRODUCTION OF 2-ISOCEPHEM DERIVATIVES OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1997-02-26 EP disclosed
US-4614614-A Process for the manufacture of optically active azetidinones CIBA-GEIGY CORPORATION (US) 1986-09-30 US disclosed
EP-0126709-A1 Process for the preparation of optically active azetidinones CIBA-GEIGY AG (CH) 1984-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293334-A1 Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase ZC3HAV1, INTS9, PRDM9 LMNA 2941/4885ALOX15 2722/4885BLM 2821/4885
US-20130018055-A1 NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES CYP1A1, AHR, CYP1B1 LMNA 1830/4885ALOX15 4606/4885BLM 678/4885
US-20020115669-A1 Oxazolidinone chemotherapeutic agents TOP1, OXA1L, TK1 LMNA 3931/4885ALOX15 1665/4885BLM 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.